All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
During the 2021 TCT Meetings Digital Experience, the GvHD Hub spoke to Mitchell E. Horwitz, Duke University School of Medicine, Durham, US. We asked, Does omidubicel reduce the rate of GvHD compared to standard cord blood transplantation?
Does omidubicel reduce the rate of GvHD compared to standard cord blood transplantation?
In this video, Horwitz discusses the results from a recent randomized phase III study comparing omidubicel, an ex vivo extended umbilical cord blood graft, to standard umbilical cord blood transplantation.
Your opinion matters
Subscribe to get the best content related to GvHD delivered to your inbox